Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer
Jie Shen(Xinjiang Medical University), Baorui Liu(Nanjing University of Chinese Medicine), Zhengyun Zou(Nanjing University of Chinese Medicine), Rafael Rosell(Hospital Universitario Dexeus), Jia Wei(North Sichuan Medical University), Li Xie(Shanghai Jiao Tong University), Carlota Costa(USP Institut Universitari Dexeus), Hao Wang(Stevens Institute of Technology), Wenxian Guan(Nanjing Tech University), Lixia Yu(Comprehensive Blood & Cancer Center), Trever G. Bivona(University of California, San Francisco), Yitao Ding(Nanjing Drum Tower Hospital), Xiaoping Qian(Cancer Institute (WIA))
Cited by 19
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k